Ondas Osman, Ates Orhan, Keles Sadullah, Yildirim Kenan, Baykal Orhan, Karamese Selina Aksak, Karamese Murat, Uslu Hakan, Yildirim Mustafa, Naldan Muhammet Emin, Ates Irem
Department of Ophthalmology, Atatürk University School of Medicine, Erzurum, Turkey.
Department of Ophthalmology, Iğdır State Hospital, Iğdır, Turkey.
Eurasian J Med. 2017 Oct;49(3):167-171. doi: 10.5152/eurasianjmed.2017.17126. Epub 2017 Jun 5.
The purpose of this study was to compare the use of an intravitreal injection of infliximab and of dexamethasone combined with vancomycin to treat experimental endophthalmitis induced by
The study was conducted between March 25 and April 13, 2012. Twenty-five six-month-old healthy rabbits were used, each weighing 2.5-3 kg. The rabbits were randomized into five groups with five animals per group. Endophthalmitis was induced by 0.1 mL (103 colony-forming units) in all groups. In group 1, injection was not implemented after the occurrence of endophthalmitis. In groups 2, 3, and 4, the following intravitreal injections were given 24 h after the occurrence of endophthalmitis: group 2, 0.1 mg/0.1 mL vancomycin; group 3, 1 mg/0.1 mL vancomycin and 1 mg/0.1 mL dexamethasone; and group 4, 1 mg/0.1 mL vancomycin and 2 mg/0.1 mL infliximab. Group 5 was the control/uninfected group. The rabbits were clinically assessed each day for seven days. On day 9, a histopathologic evaluation was performed after enucleation.
After a clinical evaluation, no statistically significant difference was found between the vancomycin+infliximab and vancomycin+dexamethasone groups (p>0.05). The difference was significant when both groups were compared with the vancomycin group (p<0.001). After the histopathologic evaluation, no statistically significant difference was found among the three groups (p>0.05).
An intravitreal injection of infliximab and of dexamethasone combined with vancomycin have similar clinical and histopathologic effects. To supplement the antibiotic treatment of endophthalmitis, infliximab in a safe dose range can be used as an alternative to dexamethasone to suppress inflammation and prevent ocular damage.
本研究旨在比较玻璃体内注射英夫利昔单抗以及地塞米松联合万古霉素治疗由[具体病原体未给出]诱导的实验性眼内炎的效果。
研究于2012年3月25日至4月13日进行。使用25只6月龄健康兔子，每只体重2.5 - 3千克。将兔子随机分为五组，每组五只。所有组均通过0.1 mL（10³ 菌落形成单位）诱导眼内炎。第1组在眼内炎发生后不进行注射。第2、3和4组在眼内炎发生24小时后进行以下玻璃体内注射：第2组，0.1 mg/0.1 mL万古霉素；第3组，1 mg/0.1 mL万古霉素和1 mg/0.1 mL地塞米松；第4组，1 mg/0.1 mL万古霉素和2 mg/0.1 mL英夫利昔单抗。第5组为对照/未感染组。每天对兔子进行临床评估，持续七天。在第9天，摘除眼球后进行组织病理学评估。
临床评估后，万古霉素 + 英夫利昔单抗组与万古霉素 + 地塞米松组之间未发现统计学显著差异（p>0.05）。当将这两组与万古霉素组进行比较时，差异显著（p<0.001）。组织病理学评估后，三组之间未发现统计学显著差异（p>0.05）。
玻璃体内注射英夫利昔单抗以及地塞米松联合万古霉素具有相似的临床和组织病理学效果。为补充眼内炎的抗生素治疗，安全剂量范围内的英夫利昔单抗可作为地塞米松的替代药物用于抑制炎症和预防眼部损伤。
